Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ellagic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.96 |
| ▸ | PKLR known ✓ | P30613 | 2/20 | 0.96 |
| ▸ | MET known ✓ | P08581 | 2/20 | 0.96 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.96 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.96 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.96 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.96 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.96 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.96 |
| ▸ | GSK3B known ✓ | P49841 | 1/20 | 0.96 |
| ▸ | ESR2 known ✓ | Q92731 | 4/20 | 0.41 |
| ▸ | ESR1 known ✓ | P03372 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.96 |
| ▸ | MAPT | P10636 | 4/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | APEX1 | P27695 | 3/20 | 0.96 |
| ▸ | RECQL | P46063 | 3/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.96 |
| ▸ | POLB | P06746 | 3/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ellagic Acid SCHEMBL2639621 | 1.00 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL30475160 | 0.98 | KDM4E (1.00) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL1645767 | 0.98 | KDM4E (1.00) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL20429 | 0.98 | KDM4E (1.00) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL29439360 | 0.98 | KDM4E (1.00) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL8686551 | 0.96 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL8686557 | 0.96 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL21590140 | 0.96 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL9146254 | 0.96 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL8686700 | 0.96 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115178243-B | MOF@COF composite porous material and preparation method and application thereof | 宜兴明灿光晶科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-115178243-A | MOF @ COF composite porous material and preparation method and application thereof | 苏州纳创佳环保科技工程有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-121826114-A | Thrombus elastography blood coagulation activation detection reagent and preparation method and application thereof | 重庆南方数控设备股份有限公司 | 2026-04-10 | — | — | CN | disclosed |
| US-20250339414-A1 | CRYSTALLINE FORMS OF ALDH2 MODULATORS | SOPHROSYNE PHARMACEUTICALS LTD (KY) | 2025-11-06 | — | — | US | disclosed |
| US-20250256005-A1 | FLOWABLE PASTE WITH ELLAGIC ACID-NICKEL COMPLEX AND USES THEREOF FOR ACTIVATING COAGULATION | OMRIX BIOPHARMACEUTICALS LTD. (IL) | 2025-08-14 | — | — | US | disclosed |
| CN-115737553-B | Ellagic acid nanosuspension with high solubility and antioxidant activity and application thereof in oral preparation, external preparation and cosmetics | 南京中医药大学 | 2025-01-03 | — | — | CN | disclosed |
| US-12171753-B2 | Crystalline forms of ALDH2 modulators | SOPHROSYNE PHARMACEUTICALS LIMITED (KY) | 2024-12-24 | — | — | US | disclosed |
| CN-115178243-B | MOF@COF composite porous material and preparation method and application thereof | 宜兴明灿光晶科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4351550-A2 | CRYSTALLINE FORMS OF ALDH2 MODULATORS | Sophrosyne Pharmaceuticals Limited (KY) | 2024-04-17 | — | — | EP | disclosed |
| CN-117729915-A | Crystalline forms of ALDH2 modulators | 索菲洛许奈制药有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230096245-A1 | CRYSTALLINE FORMS OF ALDH2 MODULATORS | SOPHROSYNE PHARMACEUTICALS LIMITED (KY) | 2023-03-30 | — | — | US | disclosed |
| US-20080220446-A1 | Method for Detecting and/or Removing Protein and/or Peptide Comprising a Cross-Beta Structure From an Aqueous Solution Comprising a Protein | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-09-11 | — | — | US | disclosed |
| EP-1928261-A1 | METHOD TO ENHANCE HATCHING PERCENTAGE OF ARTEMIA DIAPAUZING CYSTS | INVE Technologies NV (BE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1910844-A2 | CROSS-BETA STRUCTURE BINDING COMPOUNDS | Crossbeta Biosciences B.V. (NL) | 2008-04-16 | — | — | EP | disclosed |
| EP-1907863-A2 | A METHOD FOR DETECTING AND/OR REMOVING PROTEIN AND/OR PEPTIDE COMPRISING A CROSS-ß STRUCTURE FROM AN AQUEOUS SOLUTION COMPRISING A PROTEIN | Crossbeta Biosciences B.V. (NL) | 2008-04-09 | — | — | EP | disclosed |
| EP-1806120-A1 | COMPOSITION FOR PREVENTION OR ALLEVIATION OF PIGMENTATION | Otsuka Pharmaceutical Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| WO-2007039508-A1 | METHOD TO ENHANCE HATCHING PERCENTAGE OF ARTEMIA DIAPAUZING CYSTS | INVE TECHNOLOGIES NV (BE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1767101-A1 | Method to enhance hatching percentage of Artemia diapauzing cysts | Inve Technologies N.V. (BE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007008071-A2 | METHOD FOR DETECTING PEPTIDES COMPRISING A CROSS-BETA STRUCTURE | CROSSBETA BIOSCIENCES B.V. (NL) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007008072-A2 | CROSS-ß STRUCTURE BINDING COMPOUNDS | CROSSBETA BIOSCIENCES B.V. (NL) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339414-A1 | CRYSTALLINE FORMS OF ALDH2 MODULATORS | ALDH2, ALDH1A2, ALDH3A1 | MEN1 4540/4885PKLR 3585/4885MET 2751/4885 |
| US-12171753-B2 | Crystalline forms of ALDH2 modulators | ALDH2, ALDH1A2, ALDH3A1 | MEN1 4552/4885PKLR 3712/4885MET 3108/4885 |
| US-20080220446-A1 | Method for Detecting and/or Removing Protein and/or Peptide Comprising a Cross-Beta Structure From an Aqueous Solution Comprising a Protein | TIMCC, CSTB, IAPP | MEN1 1177/4885PKLR 3198/4885MET 2488/4885 |
| US-20230096245-A1 | CRYSTALLINE FORMS OF ALDH2 MODULATORS | ALDH2, ALDH1A2, ALDH3A1 | MEN1 4540/4885PKLR 3585/4885MET 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.